True Health Diagnostics genTrue Hereditary Cancer Tests
True Health Diagnostics launched genTrue hereditary cancer tests to identify patients suspected of having heritable cancer syndrome. The tests can be used to determine whether an individual has any of 26 genes associated with an increased risk for breast, colon, prostate, ovarian, endometrial, gastric, melanoma, or pancreatic cancers.
TransOmic transEdit-dual CRISPR Combinatorial Gene Knockout Kit
TransOmic is offering a new vector for its transEdit-dual CRISPR system, enabling combinatorial gene knockout to identify functional relationships between genes. The p-Clip-dual vector system can now express two single guide RNAs (sgRNAs) targeting separate genes. The new product builds on the firm's transEdit-dual CRISPR arrayed screening library, which targets 19,000 human genes with vectors expressing two sgRNAs targeting the same gene.
Cancer Genetics Complete::IO Immuno-Oncology Panel
Cancer Genetics has launched a new multiplex flow cytometry panel for use in cancer immunotherapy assessment, patient monitoring following treatment, and patient selection and stratification for clinical trials. The Complete::IO assay can help characterize the immune repertoire, immune cell populations, and the tumor microenvironment, the firm said. It detects up to 10 markers on each cell, enabling identification of rare immune cells, including central memory cells, effector cells, effector memory cells, naive CD4+ and CD8+ T cells, regulatory T and B cells, natural killer cells, and plasmacytoid dendritic cells.
For more new products and services, please visit the New Products page on our website.